[HTML][HTML] Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database …
SM Hahn, M Lee, JH Hyun, S Lim… - Cancer Research and …, 2024 - ncbi.nlm.nih.gov
Purpose Post-transplantation lymphoproliferative disorders (PTLDs) after hematopoietic
stem transplantation (HCT) or solid organ transplantation (SOT) result in poorer outcomes …
stem transplantation (HCT) or solid organ transplantation (SOT) result in poorer outcomes …
Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial
J Jin, D Ji, Z Xia, K Xue, Q Zhang, Y Liu, J Cao, X Hong… - BMC cancer, 2022 - Springer
Background R-CHOP with or without radiotherapy is the standard treatment for limited-stage
diffuse large B-cell lymphoma (DLBCL). To prevent overtreatment, we assessed whether …
diffuse large B-cell lymphoma (DLBCL). To prevent overtreatment, we assessed whether …
How to diagnose and treat CD5-positive lymphomas involving the spleen
J Cabeçadas, VE Nava, JL Ascensao… - Current …, 2021 - mdpi.com
Patients with CD5-expressing lymphomas presenting with splenomegaly are frequently
diagnosed with chronic lymphocytic leukemia. The most important differential diagnosis is …
diagnosed with chronic lymphocytic leukemia. The most important differential diagnosis is …
Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
R Karmali, F St‐Pierre, S Ma, KD Foster, J Kaplan… - …, 2023 - Wiley Online Library
Abstract Background: TAK‐659, a novel oral SYK inhibitor, has demonstrated efficacy in
heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a phase I …
heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a phase I …
2-deoxy-2-[18F] FDG PET Imaging for Therapy Assessment in Hodgkin's and Non-Hodgkin Lymphomas
N Withofs, C Bonnet, R Hustinx - PET clinics, 2024 - pet.theclinics.com
The estimated new cases of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in
the United States in 2022 are 8540 and 80,470, respectively, and the estimated deaths are …
the United States in 2022 are 8540 and 80,470, respectively, and the estimated deaths are …
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial
D Kaddu-Mulindwa, V Lesan, C Berdel… - Leukemia & …, 2022 - Taylor & Francis
Patients with diffuse large B-cell lymphoma (DLBCL) treated with the R-CHOP regime
receive a high cumulative dose of prednisone. We used computer tomography-ascertained …
receive a high cumulative dose of prednisone. We used computer tomography-ascertained …
Definition of bulky disease in early stage diffuse large B-cell lymphoma in computed tomography on coronal and transverse planes
M Ma'koseh, H Farfoura, Y Khatib, Z Omari… - Frontiers in …, 2023 - frontiersin.org
Background In early stage diffuse large B-cell lymphoma (ESDLBL), tumor bulkiness is an
important determinant of treatment and prognosis. Tumor bulk is usually measured on …
important determinant of treatment and prognosis. Tumor bulk is usually measured on …
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients …
A Augustyn, LJ Medeiros, EB Ludmir… - Leukemia & …, 2021 - Taylor & Francis
We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression
as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large …
as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large …
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B-cell lymphoma
C Thomas, S Thapa, C McLaughlin, M Halloran… - Frontiers in …, 2023 - frontiersin.org
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the US (1),
with an age-adjusted incidence rate of 7.25 per 100,000 person-years, based on SEER …
with an age-adjusted incidence rate of 7.25 per 100,000 person-years, based on SEER …
Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute
Although the current standard of care for diffuse large B-cell lymphoma (DLBCL) is six cycles
of rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone combination …
of rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone combination …